Some prior studies had suggested an increased risk of community-acquired pneumonia (CAP) in people using proton pump inhibitors (PPIs), although there was limited data to adequately define said risk. A recent meta-analysis of 13 studies (N=2098804 patients; study types included case-control studies, cohort studies, and observational studies) examined the association between PPI use and CAP and found that indeed, the incidence of CAP was higher in PPI users than in people who did not use PPIs [OR= 1.37 (95% CI= 1.22-1.53)], particularly when the PPI had been used for less than 30 days. The risk of CAP was slightly higher in PPI users who also had a history of stroke [OR =1.52 (95% CI=1.33-1.75)], although the underlying mechanism predisposing this population to higher rates of CAP is not clear. Granted, a major limitation of this meta-analysis is the absence of randomized control trials; conceivably, the relationship between CAP and PPI administration could be an association, as patients who are sicker in general are more likely to experience pneumonia as well as be prescribed a PPI. Other limitations of the study included possible misclassification of gastroesophageal reflux disease (GERD)-related aspiration pneumonitis as pneumonia, and lack of adjustment for confounding factors, such as smoking and concurrent medication use. Still, these findings invite further inquiry and suggest clinicians should be mindful of prescribing/recommending PPIs as indicated after weighing potential risks and benefits of this very common class of medications.
References:Â
Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: An Updated Meta-analysis.